The protective effect of Ursodeoxycholic Acid in prevention of hepatic damage in neurological patients treated with Sodium Valporat

Evaluation the protective effect of Ursodeoxycholic Acid on hepatic damage in patients with neurological diseases treated with Sodium Valporat

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181228042156N1

Enrollment

240

Registered

2019-05-06

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Migraine. Condition 2: Epilepsy. Condition 3: Bipolar disorder. Migraine Epilepsy and recurrent seizures Bipolar disorder

Interventions

Intervention 1: Control group: In this group, patients under Sodium Valproate treatment (15 mg/kg daily) receive placebo. Liver functional tests in this group are measured at the beginning of the stud

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Willing to participate in the study Definite diagnosis of migraine, bipolar disorder, or epilepsy Age of <18 years Not being pregnant or lactating

Exclusion criteria

Exclusion criteria: Not willing to participate in the study Systemic diseases, acute or chronic hepatic diseases (hepatitis B, C, cirrhosis), diabetes, celiac, hypertension, cardiovascular diseases, pulmonary diseases, renal diseases Age > 18 years old Using hepatotoxic drugs and antibiotics Not taking more than 10% of the administrated Ursodeoxycholic Acid

Design outcomes

Primary

Measure	Time frame
Abnormal liver functional tests. Timepoint: The outcomes are measured 3, 6, and 9 months after the initiation of the intervention. Method of measurement: Using serum separated from venous blood and ELISA method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoza Mostafaei

Zabol University of Medical Sciences

mostafaiy.rosa@gmail.com+98 54 3229 5147

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026